Upstream Bio, Inc. - 10-Q Filing
Upstream Bio filed its quarterly report (10-Q) for the period ended March 31, 2026. The filing outlines ongoing clinical development of verekitug for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and COPD, as well as financial details including cash balances and investments in marketable securities.
Tickers: $UPB